KPV or BPC-157: How Do They Differ?

KPV and BPC-157 are two distinct research peptides, with different amino acid sequences, different origins, and separate lines of study in the scientific literature. They share a catalogue and a sale format — vial, lyophilised powder — but they are not interchangeable, chemically or functionally. The confusion usually comes from both being mentioned in similar research contexts (inflammation, tissue repair), but that does not make them the same compound.

The amino acid sequence is different

KPV is a tripeptide: three amino acids, Lysine-Proline-Valine. It is the C-terminal fragment of alpha-MSH (melanocyte-stimulating hormone), and the literature studies it in isolation because it retains part of the parent molecule's activity without the rest of the chain.

BPC-157 is a fifteen-amino-acid peptide — a pentadecapeptide — derived from a fragment of a protein identified in human gastric juice ("body protection compound," where the name comes from). The full sequence and the amino acid count are the simplest structural difference between the two: KPV is a small molecule, BPC-157 is five times longer.

That size difference is not a minor detail. It changes how stable the molecule is, how it goes into solution, and what kind of in vitro assay makes sense for each one.

What the published research looks at for each one

Published studies on KPV concentrate mostly on intestinal inflammation models and on the signalling pathway associated with the melanocortin receptor. It is one of the most cited tripeptides in experimental colitis research, and it appears frequently in papers trying to isolate the anti-inflammatory portion of alpha-MSH from the rest of the molecule.

BPC-157 has a broader and more varied literature: gastrointestinal tissue repair models, tendon and ligament models, and studies on angiogenesis (new blood vessel formation) in damaged tissue. Along with TB-500, it is one of the most requested peptides in animal-model tissue repair research.

Neither compound has approval from ANMAT, the FDA, or any equivalent regulatory authority, and neither is intended for human or veterinary consumption, diagnosis or treatment. What exists is research literature in vitro and in animal models, not clinical evidence in people.

Batch documentation: what comes with each lot

PeptoClinic quotes the research peptides in its catalogue — including KPV and BPC-157 — with the purity specification and batch documentation for each lot. The standard stated in the catalogue is ≥99% by HPLC.

As a concrete example of that documentation: Janoshik Analytical analysed a combined BPC-157 and TB-500 lot on 2026-04-13 (task 204975), with 10 mg total content split into 5 mg of each peptide. It is the same kind of report that accompanies the rest of the catalogue: an external laboratory, a dated analysis, and an identifiable task number, not a generic "guaranteed purity" label with nothing behind it.

The right way to read one of these reports — what to look for, what each field means — is explained on the quality page. It is worth reviewing before comparing two suppliers by their certificate of analysis, because not every report says the same thing or carries the same level of detail.

Format: where they are alike

Here they are identical. Both are supplied as a vial of lyophilised powder, intended for in vitro and laboratory research, with USP-grade diluents available separately for whoever needs them for their research protocol. A pen presentation is not yet available for any compound in the catalogue: it is announced but not something that can be quoted today.

For Argentina specifically, BPC-157 has its own reference page with the import logistics and the customs documentation that ships with the material as laboratory reference material. It is the starting point if the question is specifically about this compound and bringing it into the country.

For laboratory research only

Both KPV and BPC-157 are supplied strictly for research use (Research Use Only, RUO): in vitro and laboratory studies. Neither is a medicine, a supplement, or a food, and neither is approved or intended for human or veterinary consumption, diagnosis or treatment. No claims about these compounds have been evaluated by ANMAT, the FDA, or any equivalent regulatory authority. PeptoClinic is not a pharmacy, a clinic, or a telehealth provider, and does not offer dosing, administration, or usage-protocol guidance.

To see the rest of the catalogue and compare other compounds studied in similar research contexts, the full catalogue is available, and for the general shipping logistics to the region, see the Argentina page.